Genmab — Oktober 2016
-
Godkendelse op til ASH virker nu meget sandsynligt
-
Nyt studie fra Janssen, phase 2, Dara mono, Lymphoma, Taiwan, 32 patienter. En indikation jeg aldrig har hørt om: https://clinicaltrials.gov/ct2/show/NCT02927925
-
-
Jeg kan huske at vi her i chatten undrede os over, at der var data med på dara-pom-dex.
-
FDA meddeler at man giver kombinationerne en hurtig handlingstid gennem systemet.
-
Priority review tildeles af FDA til lægemidler, som er til behandling af alvorlige sygdomme, og som har potentialet til at give en markant bedre sikkerhed eller behandlingseffekt end eksisterende produkter.
-
Nasal type extranodal natural killer (NK) NK-cell/T-cell lymphoma (NKTCL) is a rare extranodal lymphoma of NK-cell or T-cell origin that most commonly affects immunocompetent middle-aged men of Asian or Native American descent https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805345/
-
I første omgang går mine tanker til patienterne som venter på godkendelsen i 2. linje.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind